Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 710 | 101 | 603 |
| Samples | 354 | 62 | 289 |
| Peptides | 255 | 48 | 214 |
Function
MPL · MPL proto-oncogene, thrombopoietin receptor
In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 244 amino-acid changes on canonical ENST00000372470 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MPL · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MPL – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Acute Monocytic Leukemia | 0/1 0% | 1/25 4% |
| Endometrial Carcinoma | 4/42 10% | 17/612 3% |
| Melanoma | 1/210 0% | 47/1899 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Osteosarcoma | 3/45 7% | 0/166 0% |
| Other Solid Cancers | 2/94 2% | 20/1515 1% |
| Colorectal Carcinoma | 8/143 6% | 38/3239 1% |
| Mesothelioma | 3/62 5% | 0/165 0% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 13/1390 1% |
| Rhabdomyosarcoma | 2/33 6% | 0/171 0% |
| Gastric Carcinoma | 0/74 0% | 18/1809 1% |
| Bladder Carcinoma | 0/58 0% | 9/956 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Other Blood Cancers | 0/61 0% | 20/2725 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 5/810 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 10/1592 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Glioma | 0/52 0% | 13/2127 1% |
| Plasma Cell Myeloma | 0/44 0% | 2/305 1% |
| Neuroendocrine Tumour | 0/154 0% | 4/577 1% |
| Head and Neck Carcinoma | 3/85 4% | 6/1574 0% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 13/2550 1% |
| Breast Carcinoma | 1/144 1% | 15/3264 0% |
| Ovarian Carcinoma | 0/109 0% | 5/998 0% |
| Non-Cancerous | 3/104 3% | 1/830 0% |
Mutation Distribution
Where MPL is mutated · all tissues, split by cell line vs tissue
How many mutations in MPL were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 710 mutations in MPL
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|